APM Stock Forecast 2025-2026
Distance to APM Price Targets
APM Price Momentum
🤔 Considering Aptorum Group (APM)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest APM Stock Price Targets & Analyst Predictions
APM has shown a year-to-date change of -67.9% and a 1-year change of -87.3%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for APM. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
APM Analyst Ratings
APM Price Target Range
Latest APM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for APM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 7, 2022 | HC Wainwright & Co. | Vernon Bernardino | Buy | Initiates | $8.00 |
| Apr 2, 2019 | China Renaissance | Buy | Initiates | $22.00 |
Aptorum Group Ltd. (APM) Competitors
The following stocks are similar to Aptorum Group based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Aptorum Group Ltd. (APM) Financial Data
Aptorum Group Ltd. has a market capitalization of $6.44M with a P/E ratio of 2.9x. The company generates $431,378 in trailing twelve-month revenue with a 2.4% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -2,486.0% and return on equity of -3.0%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Aptorum Group Ltd. (APM) Business Model
About Aptorum Group Ltd.
Develops and commercializes biopharmaceutical therapies.
Aptorum Group Ltd. operates by developing innovative therapeutic projects primarily in oncology, infectious diseases, and metabolic disorders. The company makes money through advancing its drug pipeline from preclinical stages to clinical trials, seeking partnerships and collaborations to enhance its research capabilities and market reach.
Headquartered in Hong Kong, Aptorum is part of the growing influence of Asian biotech firms in the global pharmaceutical landscape. Its focus on addressing unmet medical needs highlights its commitment to innovation and improving patient outcomes.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
3
CEO
Mr. Chung Yuen Huen
Country
United Kingdom
IPO Year
N/A
Website
www.aptorumgroup.comAptorum Group Ltd. (APM) Latest News & Analysis
Synology Launches ActiveProtect: Simplifying Enterprise Data Protection with Unmatched Security, and Scalability
2 months agoSynology has launched the ActiveProtect series, a unified enterprise backup solution aimed at transforming the data backup market.
Synology's ActiveProtect series could capture market share in the competitive data backup sector, potentially boosting revenue and stock performance, impacting investor sentiment positively.
Aptorum Group Limited (NASDAQ: APM) has entered a securities purchase agreement to sell 1,535,000 Class A Ordinary Shares at $2.00 each in a registered direct offering.
Aptorum Group's direct offering of shares at $2.00 can dilute existing shares but also raises capital for potential growth, impacting stock valuation and investor sentiment.
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024
2 months agoAptorum Group Limited (NASDAQ: APM) provided a business update and financial results for H1 2024, focusing on unmet needs in oncology, autoimmune, and infectious diseases.
Aptorum Group's business update and financial results signal ongoing developments in its drug pipeline, which could affect stock performance and investor sentiment in the biopharmaceutical sector.
Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update
10 months agoAptorum Group Limited (Nasdaq: APM) reported its fiscal year 2023 financial results, focusing on advancements in oncology, autoimmune, and infectious diseases.
Aptorum Group's financial results and corporate updates indicate its progress and potential in addressing significant health issues, which can influence stock performance and investor confidence.
Why Is Aptorum (APM) Stock Up 346% Today?
1 year agoAptorum (NASDAQ: APM) shares are rising following a merger agreement with YOOV Group, where YOOV shareholders will own 90% of the combined entity post-deal.
Aptorum's merger with YOOV Group could significantly alter its equity structure, impacting share value and market perception, as YOOV shareholders will dominate the new entity.
Aptorum (NASDAQ: APM) shares are rising significantly due to a merger between its subsidiary and an AI platform, driven by AI market enthusiasm and institutional investor support.
Aptorum's rising market value reflects investor excitement over its AI merger, highlighting potential growth and innovation in biotech, which can drive stock performance and attract further investment.
Frequently Asked Questions About APM Stock
What is Aptorum Group Ltd.'s (APM) stock forecast for 2025?
Analyst forecasts for Aptorum Group Ltd. (APM) are not currently available. The stock is trading at $0.90.
Is APM stock a good investment in 2025?
Analyst ratings for APM are not currently available. The stock is currently trading at $0.90. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for APM stock?
Price predictions from Wall Street analysts for APM are not currently available. The stock is trading at $0.90.
What is Aptorum Group Ltd.'s business model?
Aptorum Group Ltd. operates by developing innovative therapeutic projects primarily in oncology, infectious diseases, and metabolic disorders. The company makes money through advancing its drug pipeline from preclinical stages to clinical trials, seeking partnerships and collaborations to enhance its research capabilities and market reach.
What is the highest forecasted price for APM Aptorum Group Ltd.?
Price targets from Wall Street analysts for APM are not currently available. The stock is trading at $0.90.
What is the lowest forecasted price for APM Aptorum Group Ltd.?
Price targets from Wall Street analysts for APM are not currently available. The stock is trading at $0.90.
What is the overall APM consensus from analysts for Aptorum Group Ltd.?
Analyst ratings for APM are not currently available. The stock is trading at $0.90.
How accurate are APM stock price projections?
Stock price projections, including those for Aptorum Group Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
